| |
|
|
Bukwang Pharmaceutical (003000) |
|
|
STOCK |
|
|
| Address |
398-1, DAEBANG-DONG, DONGJAK-GU, SEOUL |
| Home Page |
www.bukwang.co.kr
|
| Established |
1960.10.17 |
Tel |
02-828-8114 |
| Listed |
1988. 8. 5 |
IR |
02-828-8034 |
| Common shares O/S |
27,045,225 |
President |
Lee,Seong Gu |
| Preferred shares O/S |
|
No.of Employees |
540(2009. 9) |
| Sales increased on rising demand for its key product, although sale of Levovir, type-B hepatitis drug, was suspended. Net profit fell on increased financial costs, although its operating income increased. Financial status remained stable on good cash flows. |
| It is unclear whether sales of Revovir would recover because of still ongoing controversy over its side effects. Profitability is expected to improve on falling costs of imported raw materials that stem from a stronger currency. Its overseas sale of Revovir is likely to be delayed as its U.S. partner stopped clinical test. |
|
  |
(date: 2009.06, unit : %) |
| Name |
Kim Dongyeon |
Bukwang Pharmaceutical |
Kim Sanghun |
| Portion |
25.0 |
2.4 |
1.8 |
|
 |
(unit : %) |
| Sales |
Thioctacid |
14.0 |
Cost |
Raw Materials |
|
| Lagalon Susp |
10.2 |
Labors |
|
| Others |
59.3 |
Overhead |
|
|
 |
(Unit : 100Mn.Won,Won) |
| Year |
99. 6 |
00. 6 |
04.10 |
07. 6 |
08. 6 |
| Type |
SD |
SD |
BI |
SD |
SD |
| Amount |
9.72 |
5.14 |
10.80 |
5.93 |
6.43 |
|
|
|
|
